Testosterone gel for transmasc HRT: what the evidence says

What did @like.the.plant.3496 actually say?

The creator gave an overview of testosterone delivery methods for transmasculine HRT, covering injections, gel, and pellets. They said T-shots in the US are usually self-administered weekly or biweekly, while outside the US, doctors often administer them every two to three months. They noted injections cause hormone spikes and troughs, which can mean mood swings and fatigue near the next dose. On gel, they said it requires daily application, a four-to-six-hour absorption window before showering, and caution around skin contact with others. They also stated that "doctors will tell you that the changes happen at the same rate" between gel and shots, but that "the trans community believes that gel is slightly slower." Finally, they briefly mentioned subcutaneous pellets implanted every six months as a less common option.

Does the science back this up?

Mostly, yes. The pharmacokinetic picture they painted for injections is well-supported. The claim about gel causing more consistent levels is also accurate. Where things get murkier is the gel-versus-shots debate on the rate of masculinization.

Intramuscular testosterone cypionate or enanthate does produce the supraphysiologic peak and subsequent trough they described. A 2021 review by Glintborg et al. in European Journal of Endocrinology confirmed that weekly IM injections create significant intra-individual variability in serum testosterone, which correlates with mood fluctuations reported by patients. Subcutaneous injections, which the creator mentioned as using smaller needles, tend to produce a slightly flatter curve than IM, per Spratt et al. (2017, Journal of Clinical Endocrinology and Metabolism). Transdermal gel does produce more stable daily levels, but absorption varies significantly between individuals, a point the creator correctly flagged. The pellet data for transmasculine patients specifically is thin. Most pellet studies focus on cisgender men or postmenopausal women.

What did they get wrong (or right)?

They got the broad strokes right, but a few details deserve scrutiny.

• Outside-the-US injection frequency: The claim that non-US patients "go to their doctor every two to three months" is an oversimplification. Testosterone undecanoate (Nebido), common in Europe and Australia, is administered every 10 to 14 weeks, which fits the range. But many countries also offer self-administered weekly protocols. This is a geography-dependent generalization that could mislead viewers.
• The four-to-six-hour absorption window for gel: Most prescribing guidelines, including those from the Endocrine Society, suggest waiting two to six hours before washing the application site, with many sources citing two hours as sufficient. Citing four to six hours is on the conservative end but not wrong. It just may not reflect actual clinical guidance patients receive.
• Gel being "slightly slower" for masculinization: This is the most contested claim. The creator fairly acknowledged this is community belief versus medical consensus. There is limited head-to-head data comparing masculinization timelines across delivery methods in transmasculine patients specifically. Hembree et al. (2017, Journal of Clinical Endocrinology and Metabolism) does not stratify outcome timelines by delivery method. The community belief may reflect absorption variability rather than a true pharmacological difference in rate of change.
• Pellet placement: They said pellets are implanted in "your thigh or butt cheek." Clinically, subcutaneous pellets are most commonly placed in the upper buttock or hip area. Thigh placement exists but is less standard. Minor point, but worth noting for accuracy.

What should you actually know?

If you are considering testosterone as part of gender-affirming care, the delivery method conversation matters, but it is not the whole picture. Your baseline health, lifestyle, and how consistently you can follow a protocol all factor into which option fits. Gel is genuinely more forgiving of missed doses in terms of peak-trough swings, but the transfer risk is real. Studies, including one by Stahlman et al. (2012, Journal of Clinical Pharmacology), confirmed that secondary testosterone transfer via skin contact can raise serum T levels in partners and children. The creator was right to flag this. On mood and energy fluctuations with injections, the evidence supports what they said, though switching to subcutaneous injections or more frequent smaller IM doses can flatten the curve without changing the medication itself. Pellets are the least studied option in transmasculine populations. If a provider is pushing pellets hard, ask for the evidence base specific to your situation. No delivery method is universally superior. This is a conversation to have with a clinician who knows your full picture, not a TikTok comment section.